Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - Swiss Exchange 16:36:37 19/03/2025 GMT 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 30/03/2022
Director of Finance/CFO - 31/07/2024
Director TitleAgeSince
Chairman 70 19/11/2019
Director/Board Member 65 31/05/2013
Director/Board Member 80 29/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 817K
+4.73%+3.38%+19.53%-8.89% 66.56B
-1.93%+0.39%+58.62%+226.33% 56.51B
+1.07%+42.10%+42.10%+42.10% 42.98B
+3.45%+6.04%-49.46%-55.91% 40.46B
+3.04%+0.04%+62.66%-24.29% 31.91B
+10.01%+18.57%+161.59%-34.48% 31.65B
+2.68%+2.73%+70.72%+88.24% 23.35B
+2.87%+16.83%+3.78%+192.67% 19.46B
-0.13%+2.75%+67.48%+130.07% 17.18B
Average +2.87%+8.76%+34.81%+45.66% 36.67B
Weighted average by Cap. +2.79%+7.31%+43.68%+54.30%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B